<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Immunology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Immunology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский иммунологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-7221</issn><issn publication-format="electronic">2782-7291</issn><publisher><publisher-name xml:lang="en">Russian Society of Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">17281</article-id><article-id pub-id-type="doi">10.46235/1028-7221-17281-IAI</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Evaluation of ILl-10 and IL-17 in cell culture supernatants during the expansion of gamma delta T cells from the blood of patients with reactive erythema</article-title><trans-title-group xml:lang="ru"><trans-title>Определение IL-10 и IL-17 в супернатантах клеточных культур при экспансии γδ Т-лимфоцитов, выделенных из крови больных реактивными эритемами</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1188-6578</contrib-id><contrib-id contrib-id-type="spin">1052-6474</contrib-id><name-alternatives><name xml:lang="en"><surname>Sorokina</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Сорокина</surname><given-names>Екатерина Вячеславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Laboratory of Mechanisms of Regulation of Immunity, I. Mechnikov Research Institute for Vaccines and Sera; Professor, Department of Dermatovenerology and Cosmetology, Academy of Postgraduate Education, Federal Research and Practical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заведующая лабораторией механизмов регуляции иммунитета ФГБНУ «Научно-исследовательский институт вакцин и сывороток имени И.И. Мечникова»; профессор кафедры дерматовенерологии и косметологии Академии постдипломного образования ФГБУ «Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий» Федерального медико-биологического агентства</p></bio><email>sorokina-cathrine@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kalinichenko</surname><given-names>Eugen O.</given-names></name><name xml:lang="ru"><surname>Калиниченко</surname><given-names>Евгений Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), Researcher, Laboratory of Mechanisms of Regulation of Immunity</p></bio><bio xml:lang="ru"><p>к.м.н., научный сотрудник лаборатории механизмов регуляции иммунитета</p></bio><email>gladius.domini@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8143-7356</contrib-id><contrib-id contrib-id-type="spin">9846-1006</contrib-id><name-alternatives><name xml:lang="en"><surname>Bisheva</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Бишева</surname><given-names>Ирина Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Researcher, Laboratory of Mechanisms of Regulation of Immunity</p></bio><bio xml:lang="ru"><p>научный сотрудник лаборатории механизмов регуляции иммунитета</p></bio><email>ibisheva@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stolpnikova</surname><given-names>Vera N.</given-names></name><name xml:lang="ru"><surname>Столпникова</surname><given-names>Вера Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Leading Researcher, Laboratory of Mechanisms of Regulation of Immunity</p></bio><bio xml:lang="ru"><p>к.б.н., ведущий научный сотрудник лаборатории механизмов регуляции иммунитета</p></bio><email>stolpnikova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2342-9307</contrib-id><name-alternatives><name xml:lang="en"><surname>Skhodova</surname><given-names>Svetlana A.</given-names></name><name xml:lang="ru"><surname>Сходова</surname><given-names>Светлана Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biology), Leading Researcher, Laboratory of Mechanisms of Regulation of Immunity</p></bio><bio xml:lang="ru"><p>к.б.н., ведущий научный сотрудник лаборатории механизмов регуляции иммунитета</p></bio><email>skhodova2009@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.I. Mechnikov Research Institute of Vaccines and Serums, Russian Academy of Medical Sciences, Moscow, Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБНУ НИИВС им. И.И. Мечникова, Москва, Россия</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Medical and Biological Agency, Moscow, Russian Federation</institution></aff><aff><institution xml:lang="ru">Федеральный научно-клинический центр специализированных видов медицинской помощи и медицинских технологий Федерального медико-биологического агентства</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-08-05" publication-format="electronic"><day>05</day><month>08</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-01-18" publication-format="electronic"><day>18</day><month>01</month><year>2026</year></pub-date><volume>29</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>81</fpage><lpage>92</lpage><history><date date-type="received" iso-8601-date="2025-06-12"><day>12</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-24"><day>24</day><month>07</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Sorokina E.V., Kalinichenko E.O., Bisheva I.V., Stolpnikova V.N., Skhodova S.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Сорокина Е.В., Калиниченко Е.О., Бишева И.В., Столпникова В.Н., Сходова С.А.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Sorokina E.V., Kalinichenko E.O., Bisheva I.V., Stolpnikova V.N., Skhodova S.A.</copyright-holder><copyright-holder xml:lang="ru">Сорокина Е.В., Калиниченко Е.О., Бишева И.В., Столпникова В.Н., Сходова С.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rusimmun.ru/jour/article/view/17281">https://rusimmun.ru/jour/article/view/17281</self-uri><abstract xml:lang="en"><p>Reactive erythemas represent a group of dermatoses with complex immunogenesis as in a number of autoinflammatory disorders, with probable involvement of γδ T cell subpopulations. Despite important role of IL-17, its excessive synthesis, e.g., by γδ T cells, may induce autoinflammation. On the contrary, IL-10 plays a key role in the control of innate immune responses by suppressing the function of monocytes/macrophages and reducing production of pro-inflammatory cytokines by these cells. Our aim was to assess the content of IL-17 and IL-10 in cell culture supernatants from γδ T cells expanded by <italic>in vitro</italic> cultivation of blood lymphocytes from the patients with erythema. The cultures were supplied by zoledronate, IL-2 and IL-15. Materials and methods: Peripheral blood mononuclear cells (PBMC) were isolated from 8 patients with reactive erythema (5 patients with erythema multiforme, 1 patient with ring–shaped centrifugal erythema, 2 patients with erythema migrans, an early form of Lyme disease) and two healthy donors aged 23 to 70 years. A modified van Ackeretal method (2016) was used to culture γδ T lymphocytes. Spontaneous and induced cytokine secretion was determined by solid-phase ELISA using Human IL-17 ELISA Kit (RK00397, ABclonal BiotechnologyCo., China) and Interleukin-10-ELISA-BEST (Vector Best, Russia) according to the manufacturers' instructions. Results and Conclusion. In patients with reactive erythema, 3.1% to 62.8% of cells with γδ TCR expression of were obtained by 7 days of cultivation with zoledronate, IL-2 and IL-15. The lowest percentage of these cells was observed in blood cell culture from patients with continuously recurrent erythema multiforme and ring-shaped centrifugal erythema. In the group of patients studied, high levels of induced IL-17 production may suggest the presence of autoimmune component in pathogenesis of the disease and/or to reflect the severity of its course. The effectiveness of therapy in the examined patients correlated with ability of blood cells to <italic>in vitro</italic> synthesis and release of IL-10. It has been shown that high values of spontaneous and induced IL-10 production are associated with good response to therapy (significant clinical improvement, long-term clinical remission). Meanwhile, suboptimal therapeutic effect (rapid development of relapses after the end of the course of therapy) was detected in cases of low spontaneous and induced IL-10 production. The data obtained indicate the probable prognostic significance of these analytes as biomarkers. In future, the determination of these factors in MLPC culture in patients with studied pathologies may improve assessment of therapeutic efficiency and predict the course of the disease. However, further research is required in this area, including studies of other disorders.</p></abstract><trans-abstract xml:lang="ru"><p>Реактивные эритемы – группа дерматозов со сложным иммуногенезом, в котором, как и в развитии многих аутовоспалительных заболеваний, принимают участие субпопуляции γδ Т-клеток. Несмотря на важную роль IL-17 в функционировании иммунной системы, его избыточный синтез, в том числе γδ Т-клетками, способен индуцировать аутовоспаление. При этом IL-10, напротив, играет ключевую роль в контроле врожденных иммунных реакций, подавляя функцию моноцитов/макрофагов. Цель – определение содержания IL-10 и IL-17 в супернатантах клеточных культур при экспансии γδ Т-лимфоцитов, выделенных из крови больных реактивными эритемами. Мононуклеарные клетки периферической крови (МНПК) выделяли от 8 пациентов с реактивными эритемами и двух здоровых доноров в возрасте от 23 до 70 лет и культивировали для селективного размножения γδ T-лимфоцитов в среде RPMI-1640 с добавлением 10%-ной аутологичной сыворотки (первые 3 суток – с 3 мкМ золедроната, далее 4 суток с IL-2 (100 МЕ/мл) и IL-15 (10 нг/мл)). Клеточный состав культуры анализировали методом проточной цитометрии. Спонтанную и индуцированную секрецию цитокинов определяли методом твердофазного ИФА с использованием наборов Human IL-17 ELISA Kit (RK00397, ABclonal Biotechnology Co., Китай) и «Интерлейкин-10-ИФА-БЕСТ» (АО «Вектор-Бест», Россия) согласно инструкциям производителей. Обработку данных осуществляли с построением калибровочных кривых путем применения онлайн-калькулятора ELISA calculation sheet (Hycult Biotech, США). У пациентов с реактивными эритемами в процессе культивирования с золедронатом, IL-2 и IL-15 было получено к 7-му дню культивирования до 62,8% МНПК с экспрессией γδ TCR. В группе обследованных больных выявлены высокие уровни индуцированной продукции IL-17, что может указывать на наличие аутоиммунного компонента в патогенезе заболевания или отражать тяжесть течения. Показано, что высокие значения спонтанной и индуцированной продукции IL-10 ассоциируются с длительной ремиссией. Полученные данные указывают на вероятную прогностическую значимость этих аналитов как биомаркеров. Однако необходимы дальнейшие исследования в этом направлении, в том числе при других нозологических формах.</p></trans-abstract><kwd-group xml:lang="en"><kwd>erythema multiforme</kwd><kwd>ring-shaped erythema</kwd><kwd>migrating erythema</kwd><kwd>gamma delta T lymphocytes</kwd><kwd>interleukins</kwd><kwd>biomarkers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>многоформная эритема</kwd><kwd>кольцевидная эритема</kwd><kwd>мигрирующая эритема</kwd><kwd>гамма дельта Т-лимфоциты</kwd><kwd>интерлейкины</kwd><kwd>биомаркеры</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bernardini N., Skroza N., Tolino E., Mambrin A., Anzalone A., Balduzzi V., Colapie-tra D., Marchesiello A., Michelini S., Proietti I., Potenza C. IL17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art. Int. J. Dermatol., 2019, Vol. 59, no. 4, pp. 406-411.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Bøyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. Suppl., 1968, Vol. 97, рр. 77-89.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cai Y., Shen X., Ding C., Qi C., Li K., Li X., Jala V.R., Zhang H., Wang T., Zheng J., Yan J. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity, 2011, Vol. 35, no. 4, pp. 596-610.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Cheuk S., Wiken M., Blomqvist L., Nylén S., Talme T., Ståhle M., Eidsmo L. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J. Immunol., 2014, 192, no. 7, pp. 3111-3120.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Khan M.W.A., Otaibi A.A., Sherwani S., Alshammari E.M., Al-Zahrani S.A., Khan W.A., Alsukaibi A.K.D., Alouffi S., Khan S.N. Optimization of methods for peripheral blood mononuclear cells isolation and expansion of human gamma delta T cells. Bioinformation, 2021, Vol. 17, no. 3, рр. 460-469.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Laggner U., Di Meglio P., Perera G.K., Hundhausen C., Lacy K.E., Ali N., Smith C.H., Hayday A.C., Nickoloff B.J., Nestle F.O. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J. Immunol., 2011, Vol. 187, no. 5, pp. 2783-2793.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Roth S.A., Simanski M., Rademacher F., Schroder L., Harder J. The pattern recognition receptor NOD2 mediates Staphylococcus aureus-induced IL-17C expression in keratinocytes. J. Invest. Dermatol., 2014, Vol. 134, no. 2, pp. 374-380.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Rouvier E., Luciani M.F., Mattei M.G., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA in stability sequences, and homologous to a herpesvirus Saimiri Gene. J. Immunol., 1993, Vol. 150, no. 12, pp. 5445-5456.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Tamassia N., Arruda-Silva F., Calzetti F., Lonardi S., Gasperini S., Gardiman E., Bianchetto-Aguilera F., Benerini Gatta L.B., Girolomoni G., Mantovani A., Vermi W., Cassatella M.A. A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It. Front. Immunol., 2018, Vol. 9, 795. doi: 10.3389/fimmu.2018.00795.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Teunissen M.B., Munneke J.M., Bernink J.H., Bernink J.H., Spuls P.I., Res P.C., Velde A.T., Cheuk S., Brouwer M.W., Menting S.P., Eidsmo L., Spits H., Hazenberg M.D., Mjösberg J. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients. J. Invest. Dermatol., 2014, Vol. 134, no. 9, pp. 2351-2360.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Van Acker H.H., Anguille S., Willemen Y., Van den Bergh J.M., Berneman Z.N., Lion E., Smits E.L., van Tendeloo V.F. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J. Hematol. Oncol., 2016, Vol. 9, no. 1, 101. doi: 10.1186/s13045-016-0329-3.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Venken K., Jacques P., Mortier C., Labadia M.E., Decruy T., Coudenys J., Hoyt K., Wayne A.L., Hughes R., Turner M., Van Gassen S., Martens L., Smith D., Harcken C., Wahle J., Wang C.-T., Verheugen E., Schryvers N., Varkas G., Cypers H., Wittoek R., Piette Y., Gyselbrecht L., Van Calenbergh S., van den Bosch F., Saeys Y., Nabozny G., Elewaut D. ROR gamma t inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in spondyloarthritis patients. Nat. Commun., 2019, Vol. 10, no. 1, 9. doi: 10.1038/s41467-018-07911-6.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Xu M., Dong C. IL-25 in allergic inflammation. Immunol. Rev., 2017, Vol. 278, no. 1, pp. 185-191.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Xu M., Lu H., Lee Y.H., Wu Y., Liu K., Shi Y., An H., Zhang J., Wang X., Lai Y., Dong C. An Interleukin-25-mediated autoregulatory circuit in keratinocytes plays a pivotal role in psoriatic skin inflammation. Immunity, 2018, Vol. 48, no. 4, pp. 787-798.e4.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., Armitage R.J. Human IL-17: a novel cytokine derivided from T cells. J. Immunol., 1995, Vol. 155, no. 12, pp. 5483-5486.</mixed-citation></ref></ref-list></back></article>
